What is it? Why is it important?

The monitoring strategy should be risk-based. This means that the extent of monitoring activities should be adapted according to expected study risks (e.g. study complexity, inclusion of vulnerable participants, experience of site study team).

Monitoring activities should be supervised by an experienced professional.

 

The extent of study monitoring required is defined by inherent study risks, such as:

  • Higher-risk studies (e.g. category B or C versus A)
  • Inclusion of vulnerable population (e.g. children or adolescents, patients without capacity, pregnant women, participants with legal guardians)
  • Complexity and nature of the study design (e.g. randomized, blinded studies, placebo studies, cross-over)
  • Large numbers of recruited participants

What do I need to do?

As a SP-INV and monitor familiarise yourself with ICH-GCP, which gives detailed guidance on how to organize and implement the monitoring of your study, including:

In order to ensure ICH-GCP knowledge and compliance, the study SP-INV is required to have adequate documented GCP training (e.g. based on country specific GCP training requirements).

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular guideline

  • Glossary: definition monitoring
  • 3.11.4 Monitoring
  • 3.10.1.3 Risk control

ICH E8 – see in particular guideline

  • 6.13 Data management – centralized monitoring
  • 6.2.1 Safety monitoring

ISO 14155 Medical Device – see in particular section (access liable to costs)

  • 6.7 Monitoring plan
  • 9.2.4 Monitoring

Swiss Law

ClinO – see in particular article

  • Art. 2b Definition of intervention
  • Art. 19 - 20 Study categorisation

ClinO-MD – see in particular article

  • Art. 6 Categorisation of clinical investigation
  • Art. 6a Categorisation of performance studies

HRO – see in particular article

  • Art. 3a Definition of research
  • Art. 7 Research categorisation

 

Documents

Abbreviations
  • ClinO - Clinical Trials Ordinance
  • ClinO-MD – Ordinance on Clinical Trials of Medical Devices
  • CTU – Clinical Trials Unit
  • GCP – Good Clinical Practice
  • HRO – Human Research Ordinance
  • ICH – International Council for Harmonisation 
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • ISO – International Organisation for Standardisation
  • SP-INV – Sponsor-Investigator
Development ↦ Monitoring ↦ Montoring Strategy ↦ Aim
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Development ↦ Monitoring ↦ Montoring Strategy ↦ Aim